Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Trump Buys SpaceX Shares After Record IPO 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Add as a preferred source on Google
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
